ALPMF (Astellas Pharma) Payments of Debt: $-1,860 Mil (TTM As of Mar. 2026)


ALPMF Astellas Pharma Inc ALPMF
73 GF Score
Price $14.15
GF Value $14.60
Valuation Fairly Valued
! 4 Warning Signs
View Full Analysis

What is Astellas Pharma Payments of Debt?

Astellas Pharma ALPMF 73 Payments of Debt is $-1,860 Mil as of Mar. 2026. GuruFocus rates ALPMF with a GF Score™ of 73/100 and a GF Value™ of $14.60 (Fairly Valued). The stock has 4 warning signs investors should review.

Astellas Pharma's Payments of Debt for the three months ended in Mar. 2026 was $-1,007 Mil.

Astellas Pharma's Payments of Debt for the trailing twelve months (TTM) ended in Mar. 2026 was $-1,860 Mil.

Astellas Pharma Payments of Debt Related Terms

Astellas Pharma Payments of Debt Historical Data

* Premium members only.

The historical data trend for Astellas Pharma's Payments of Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Astellas Pharma Payments of Debt Chart

Astellas Pharma Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Payments of Debt
Get a 7-Day Free Trial Premium Member Only Premium Member Only -506.00 -486.29 -169.40 -1,935.64 -1,685.24

Astellas Pharma Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Payments of Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -538.34 -46.14 -570.45 -236.63 -1,006.56
ALPMF
73GF Score
Astellas Pharma Inc ALPMF
Payments of Debt is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Astellas Pharma Payments of Debt Calculation

Payments of Debt represents all the cash outflow from debt, including both long-term debt and short-term debt.

Payments of Debt for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1,860 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Payments of Debt →
What does a Payments of Debt of $-1,860 Mil mean?
Astellas Pharma (ALPMF) has a Payments of Debt of $-1,860 Mil as of Mar. 2026. Payments of Debt is all the cash outflow from debt, including both long-term debt and short-term debt. View historical data on Astellas Pharma and its competitors.
Is Astellas Pharma's Payments of Debt too high?
Astellas Pharma's current Payments of Debt is $-1,860 Mil. Overall, Astellas Pharma has a GF Score™ of 73/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Astellas Pharma's Payments of Debt compare to LLY and JNJ?
Astellas Pharma's Payments of Debt of $-1,860 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Payments of Debt for a Drug Manufacturers company?
A good Payments of Debt depends on the Drug Manufacturers industry context. However, Payments of Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Payments of Debt mean?
A high Payments of Debt can signal that a stock is expensive relative to its fundamentals. Payments of Debt is all the cash outflow from debt, including both long-term debt and short-term debt. View historical data on Astellas Pharma and its competitors. Astellas Pharma's current Payments of Debt is $-1,860 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Astellas Pharma stock overvalued right now?
Based on GuruFocus' analysis, Astellas Pharma (ALPMF) is currently considered Fairly Valued. The stock's GF Value™ is $14.60, compared to a current price of $14.15 — trading 3.1% below its estimated fair value. The current Payments of Debt is $-1,860 Mil. Astellas Pharma's overall GF Score™ is 73/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Payments of Debt calculated?
Payments of Debt is calculated from a company's financial statements. For Astellas Pharma (ALPMF), the current Payments of Debt is $-1,860 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Astellas Pharma (ALPMF) Overvalued in 2026?

Based on GuruFocus' analysis, Astellas Pharma stock appears to be undervalued. The current stock price of $14.15 is trading 3.1% below its estimated GF Value™ of $14.60. GuruFocus considers Astellas Pharma to be Fairly Valued.

Key valuation signals for ALPMF:

  • Payments of Debt: $-1,860 Mil
  • GF Value™: $14.60 vs. price of $14.15 (3.1% below fair value)
  • GF Score™: 73/100 with 4 warning signs

No single metric tells the full story. See the ALPMF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Astellas Pharma Business Description

Address 2-5-1 Nihonbashi-Honcho, Chuo-ku, Tokyo, JPN, 103-8411
Astellas Pharma Inc is a specialty international pharmaceutical company. The company focuses on accelerating the discovery, development, and commercialization of ground-breaking innovations that could redefine expectations of care for difficult-to-treat diseases. The group is committed to driving innovation in immuno-oncology, gene therapy, mitochondria, blindness and regeneration, and targeted protein degradation. Its core products include anticancer agents like XTANDI, XOSPATA, and PADCEV; VEOZAH for the treatment of vasomotor symptoms due to menopause; Betanis / Myrbetriq / BETMIGA for the treatment of overactive bladder (OAB); and Prograf, an immunosuppressant for organ transplantation.
73GF Score

Get the complete analysis for ALPMF

Payments of Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$14.15
Price
$14.60
GF Value